Our lead program VENT-02, a brain-penetrant NLRP3 inhibitor, is in a Phase 2 trial for Parkinson’s disease. Our second lead program – VENT-03, a first-in-class cGAS inhibitor – is expected to enter Phase 2 development for lupus in 2025.
Our robust pipeline of differentiated therapeutics aims to address biologically validated drug targets that have been previously considered undruggable or areas where current therapies are insufficient for patients.
Our pipeline is powered by ReSOLVE® – a powerful platform combining the latest advances in AI/ML, protein science, structural biology, and biophysics to substantially increase the speed and accuracy of small-molecule drug discovery.
